Valve-in-valve transcatheter aortic valve replacement (VIV TAVR) is currently indicated for
the treatment of failed surgical tissue valves in patients determined to be at high surgical risk …

The use of bioprosthetic valves for treating patients with severe valve disease has increased
over the last 2 decades, and, as a consequence, a growing number of patients with failing …

Objectives The aim of this study was to assess the outcomes of severe prosthesis-patient
mismatch (PPM) in the TVT (Transcatheter Valve Therapy) Registry in patients undergoing …

Background Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) is
increasingly used to treat degenerated surgical bioprostheses. Bioprosthetic valve fracture …

Aims: Bioprosthetic valve fracture (BVF) may improve transvalvular gradients and
transcatheter heart valve (THV) expansion during VIV interventions. However, the optimal …

Introduction Valve-in-valve (VIV) transcatheter valve replacement has emerged as a feasible
and potentially safer treatment option for failed bioprosthetic surgical valves (BSVs) …

Background Prior to the approval of the Sapien valve in 2020, there were no commercially
available short-frame valves for transapical mitral valve-in-valve (MVIV) implantation. In …

Transcatheter aortic valve-in-valve replacement presents a viable, minimally invasive
approach to replacing degraded bioprosthetic surgical valves. The major drawback of this …

Objectives The aim of this study was to investigate the degree of functional improvement of a
transcatheter heart valve (THV) for valve‐in‐valve after bioprosthetic valve fracture (BVF) of …

Degeneration of surgical bioprosthetic heart valves (BPVs) occurs in up to one third of
surviving patients within a decade of implantation and is a common cause of cardiovascular …